Phase 2 Completed N=25 Randomized Double-blind Basic Science

Effects of Dronabinol (Oral THC) on Cannabis Use

Marijuana Smoking

Source: ClinicalTrials.gov NCT01394185 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Aug 2017

Primary outcomePrimary: Marijuana Self-administration - Progressive Ratio — 5.2; 4.5; 4.4 Progressive Ratios Completed

Summary

Study participants received dronabinol (0, 120mg/day and 240mg/day) for 12 consecutive days in a randomized order. During each dronabinol maintenance period they were able to self-administer active or placebo cannabis using either a progressive ratio schedule or choice between cannabis and monetary alternative.

Outcome Measures

Outcome	Result	p-value
PRIMARY Marijuana Self-administration - Progressive Ratio	5.2; 4.5; 4.4	—
PRIMARY Marijuana Self-administration - Drug Vs Money Choice	3.5; 2.3; 2.5	—

Eligibility Criteria

Inclusion Criteria

Current use of marijuana
Able to give informed consent

Exclusion Criteria

Daily use of psychoactive medication
Current Axis I psychiatric disorder other than dependence on cannabis or nicotine, or abuse of drugs or alcohol
Women who are pregnant, breast feeding, or planning to become pregnant within the next 3 months
Those seeking treatment for cannabis-related problems or using cannabis under the guidance of a physician for a medical disorder
Uncontrolled or unstable cardiovascular disease
Allergy to sesame oil

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01394185). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.